In conclusion, our pilot study showed that short-term empagliflozin administration induces a significant effect on several specific markers of mineral metabolism, including serum phosphate, PTH and FGF-23, but this effect was seen only in the diabetic patients with CKD. The gene discussed is FGF23; the disease is chronic kidney disease.